Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Kura Oncology (KURA) EBIT Margin (2024 - 2025)

Kura Oncology (KURA) has disclosed EBIT Margin for 2 consecutive years, with 464.82% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 463257.0% to 464.82% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 410.27% through Dec 2025, down 1093195.0% year-over-year, with the annual reading at 86.64% for FY2025, 1964.0% down from the prior year.
  • EBIT Margin for Q4 2025 was 464.82% at Kura Oncology, down from 355.29% in the prior quarter.
  • The five-year high for EBIT Margin was 13104.85% in Q3 2024, with the low at 464.82% in Q4 2025.